KEY TAKEAWAYS
- The study aimed to investigate the prognostic significance and therapeutic implications of TROAP across different subtypes of RCC.
- Researchers found that elevated TROAP levels signify aggressive RCC and therapy resistance.
Trophinin Associated Protein (TROAP) has been implicated in various tumors; however, its role in renal cell carcinoma (RCC) remains largely unexplored.
Qinglin Tan and the team aimed to investigate the prognostic and therapeutic significance of TROAP in RCC, covering multiple subtypes.
Researchers first analyzed TROAP expression across various tumors using data from the TCGA pan-cancer cohort. They then assessed TROAP’s prognostic value in three TCGA RCC cohorts and a local cohort.
To further explore TROAP’s role, they performed functional enrichment analysis, examined somatic mutations and copy number variations, evaluated therapeutic response, and conducted in vitro experiments to investigate TROAP’s biological characteristics.
The results showed that TROAP was a negative factor in TCGA RCC datasets and the local cohort. Functional enrichment and in vitro experiments showed that TROAP acts as an oncogene, promoting tumor growth. The link between TROAP expression and gene mutations in RCC seems minimal. Moreover, high TROAP levels are linked to lower effectiveness of RCC treatments, including nivolumab and everolimus.
The study concluded that TROAP is a crucial RCC biomarker for prognosis and therapy response. High TROAP expression indicates aggressive tumor behavior and resistance to conventional treatments, highlighting its potential as a target for personalized RCC therapies.
The study was funded by the Guangdong Basic and Applied Basic Research Foundation.
Source: https://pubmed.ncbi.nlm.nih.gov/39153983/
Tan Q, Kong P, Chen G, et al. (2024). “Evaluating trophinin associated protein as a biomarker of prognosis and therapy response in renal cell carcinoma.” BMC cancer, 24(1), 1021. https://doi.org/10.1186/s12885-024-12802-9
